Recursion Pharmaceuticals Cash Flow Statement (2020-2026) | RXRX

Cash Flow Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income (Quarter)
-40.93M-46.40M-64.96M-55.98M-66.19M-62.57M-60.98M-65.33M-76.73M-93.02M-93.00M-91.37M-97.54M-95.84M-178.91M-202.49M-171.90M-162.25M-108.12M-117.50M
Depreciation and Depletion (Quarter)
2.40M2.50M2.50M2.70M2.70M2.90M3.10M3.60M4.00M4.20M4.20M4.00M4.10M4.00M6.20M
Share-based Compensation (Quarter)
5.32M3.36M4.34M5.63M5.67M8.91M7.70M8.81M11.81M16.79M16.09M16.13M16.52M18.25M30.78M36.06M26.16M25.24M23.76M22.21M
Deferred Taxes (Quarter)
-0.42M-4.60M
Gains from Investment Securities (Quarter)
-2.94M2.94M1.55M-2.14M4.54M-4.78M-0.72M-0.02M1.85M1.50M0.56M5.94M-5.85M-16.99M-4.82M-4.27M2.44M-2.90M-1.67M
Asset Writedowns and Impairment (Quarter)
2.81M1.17M0.02M0.11M5.96M
Cash from Operations (Quarter)
-33.65M-33.05M-61.16M77.39M-61.62M-54.54M-44.75M-73.32M-67.47M-72.92M-74.08M-102.30M-82.22M-59.23M-115.43M-131.96M-76.42M-117.36M-46.07M-81.10M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF) (Quarter)
2.33M2.44M2.24M2.77M2.79M2.99M3.21M3.73M5.54M7.58M7.55M7.38M8.97M7.20M12.95M19.33M23.85M21.04M19.48M19.67M
Change in Working Capital
Change in Receivables (Quarter)
-0.01M-0.02M
Change in Account Payables (Quarter)
0.07M3.13M-3.51M1.34M-0.99M0.71M0.69M-0.34M-2.52M2.19M-0.32M1.17M-1.34M-1.51M8.12M3.69M-4.84M-5.89M4.42M2.07M
Change in Accured Expenses (Quarter)
1.13M10.13M1.64M-15.90M1.07M2.09M12.16M-9.85M6.20M7.58M2.78M-18.86M7.51M6.35M10.52M-26.59M11.38M-8.03M15.84M-18.45M
Other Working Capital Changes (Quarter)
4.86M-2.36M5.38M-0.09M-2.73M126.81M-123.99M-12.13M6.69M6.78M-42.41M-26.29M3.92M28.45M-9.76M-13.62M-6.63M-2.92M-14.75M
Investing Activities
Capital Expenditures (Quarter)
-18.65M34.57M4.46M4.34M16.48M-17.72M33.97M0.24M-0.24M9.88M-7.45M6.65M1.18M4.56M1.30M1.15M-0.88M-0.23M6.44M
Change in Intangibles (Quarter)
0.30M0.17M0.08M0.35M3.00M0.35M2.16M0.08M
Acquisitions (Quarter)
0.07M-277.10M
Divestments (Quarter)
-4.44M
Change in Acquisitions & Divestments (Quarter)
69.19M147.65M21.41M61.55M0.48M
Cash from Investing Activities (Quarter)
-6.21M-193.87M-52.24M143.30M4.94M52.98M-7.98M-5.34M-2.05M-0.35M-2.49M-6.65M-4.18M-4.56M275.46M-7.27M-5.81M-2.55M-1.24M-0.34M
Financing Activities
Cash from Financing Activities (Quarter)
463.70M-11.10M3.80M2.08M2.67M2.34M147.26M1.92M3.79M53.77M80.66M13.90M263.12M16.46M10.64M40.53M97.66M251.34M132.01M-3.47M
Additional items
Exchange Rate Effect (Quarter)
-0.31M-0.00M0.18M-0.12M0.12M-0.22M-0.12M0.40M-3.47M4.83M9.26M1.87M2.09M-3.83M
Change in Cash (Quarter)
423.84M-238.02M-109.61M222.78M-54.02M0.78M94.22M-76.73M-65.55M-19.62M4.22M-95.28M176.60M-46.92M167.19M-93.87M24.69M133.30M86.78M-88.74M
Free Cash Flow (Quarter)
-15.00M-67.62M-65.62M73.05M-78.10M-36.82M-78.71M-73.56M-67.23M-82.80M-66.63M-108.95M-83.40M-63.79M-116.73M-133.10M-75.53M-117.13M-52.51M-81.10M
Net Cash Flow (Quarter)
423.84M-238.02M-109.61M222.78M-54.02M0.78M94.53M-76.73M-65.73M-19.50M4.09M-95.06M176.72M-47.33M170.66M-98.70M15.43M131.43M84.69M-84.91M